Celcuity Inc. (NASDAQ:CELC) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET

Company Participants

Robert Uhl - Westwicke Partners, LLC

Brian Sullivan - Co-Founder, Chairman & Chief Executive Officer

Vicky Hahne - Chief Financial Officer

Igor Gorbatchevsky - Chief Medical Officer

Conference Call Participants

Maurice Raycroft - Jefferies

Boris Peaker - Cowen & Co.

Operator

Good afternoon, and welcome to Celcuity Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder this conference is being recorded.

I would now like to turn the conference over to your host, Robert Uhl. Please go ahead sir.

Robert Uhl

Thank you, operator. Good afternoon, everyone, and welcome to Celcuity's second quarter 2022 financial results and business update webcast and conference call. Thank you for joining us. Earlier today, Celcuity Inc. released financial results for the second quarter ended June 30, 2022. The press release can be found on the Investors section of the company website. Joining me on the call today are Brian Sullivan, Celcuity's Chief Executive Officer and Co-Founder; Vicki Hahne, Chief Financial Officer; as well as Igor Gorbatchevsky, Chief Medical Officer, who will be available during Q&A.

Before we begin, I would like to remind investors that our comments today will include some forward-looking statements. These statements involve a number of risks and uncertainties, which are outlined in today's press release and in our reports and filings with the SEC. Actual events or results may differ materially from those projected in the forward-looking statements. Such forward-looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. On this call, we will also refer to non-GAAP financial measures. These non-GAAP measures are used by management to make strategic decisions, forecast future results and evaluate the company's current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table reconciling the non-GAAP financial measures to GAAP measures in today's press release.

And with that, I'd like to turn the call over to Brian Sullivan, CEO of Celcuity.

Brian Sullivan

Thanks, Robert, and good afternoon, everyone, and thank you for joining us today. As always, we really appreciate your continued support at Celcuity. I am happy to report that over the past few months our team has made significant progress on a variety of fronts to advance the development of gedatolisib. On this call we will review the regulatory status of gedatolisib’s clinical development program, our pivotal phase 3 trial on breast cancer and our recent financing activity.